Physicians' Academy for Cardiovascular Education

Antibodies against PCSK9: A new LDL-c lowering therapy?

3' education - Mar. 31, 2013 - CVC 2013 - Dr. Kees Hovingh, Amsterdam



Brief CME. An introduction by Dr. Kees Hovingh, AMC, Amsterdam about the discovery of PCSK9 and the development of antibodies as a novel strategy to reduce LDL-c.
 

Role of PCSK9

In the regulation of LDL cholesterol
A 3D video animation on the role of PCSK9 (with couresy of Amgen)
Advancing the Understanding of Cholesterol Metabolism:The Role of Proprotein Convertase Subtilisin-like/kexin Type 9 (PCSK9) in the Regulation of Low-Density Lipoprotein Cholesterol (LDL-C) and LDL Receptors (LDL-Rs) Read more...

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: